Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03661515 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML(FLAGINEXOR) | completed | Phase 1 | 16 | PETHEMA FoundationOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT01839240 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT00462761 | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | completed | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 2 | May 11, 2020 | clinicaltrials |
| NCT01830777 | Brentuximab Vedotin + Re-induction Chemotherapy for AML | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02573363 | Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 25 | University of ChicagoOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 18, 2020 | clinicaltrials |
| NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02892318 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02316964 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 8 | Sumithira VasuOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | completed | Phase 1 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01349049 | Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 90 | Daiichi SankyoINDUSTRY | 1 | Mar 2, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT00783653 | Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | completed | Phase 1 / Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03882281 | Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia(CML) | completed | Phase 1 | 12 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01629082 | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01300572 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | completed | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02995655 | CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | completed | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00321581 | AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02909972 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 55 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01702155 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 69 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02674763 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | completed | Phase 1 | 62 | ImmunoGen, Inc.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00780104 | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias(UPCC 02407) | completed | Phase 1 | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT02253277 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients(CoRNea) | completed | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT01463046 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 29 | University of California, San FranciscoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01700751 | Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | completed | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 46 | Agios Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 8, 2019 | clinicaltrials |
| NCT01031368 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 29 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT02016729 | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | completed | Phase 1 | 36 | Kartos Therapeutics, Inc.INDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02678338 | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | completed | Phase 1 | 20 | Gilead SciencesINDUSTRY | 1 | Feb 21, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2020source: clinicaltrials